Claims for Patent: 7,271,143

Summary for Patent: 7,271,143

Title:	Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
Abstract:	Compositions of the polypeptide SEQ ID NO:1, SEQ ID NO:2, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents. The invention further relates to combination compositions and/or therapy regimens, comprising the polypeptide SEQ ID NO:1 and/or SEQ ID NO:2 and one or more currently used plasminogen activators.
Inventor(s):	Higazi; Abd. Al-Roof (Shimshon, IL)
Assignee:	Thrombotech Ltd. (Nazareth Illit, IL)
Application Number:	10/386,777
Patent Claims:	1. A polypeptide, having an inhibitory effect on vasoactivity induced by plasminogen activators, wherein said polypeptide is Ac-RMAPEEIIMDRPFLYVVR-amide (SEQ ID NO: 2). 2. The polypeptide according to claim 1, wherein the plasminogen activators includes tcuPA, tPA, streptokinase, rt-PA, rt-PA derivatives, APSC, recombinant scuPA prourokinase or the covalent cross linked scuPA/suPAR complex. 3. A composition comprising an effective amount of the polypeptide according to claim 1 to reduce hemorrhage caused by a fibrinolytic agent. 4. The composition according to claim 3, further comprising a fibrinolytic agent selected from the group consisting of scuPA, tPA, uPA, tcuPA, streptokinase, rt-PA, alteplase, rt-PA derivatives, reteplase, lanoteplase, TNK-rt-PA, anisoylated plasminogen streptokinase complex, anistreplase, or a streptokinase derivative. 5. A method of enhancing the fibrinolytic activity of a fibrinolytic agent by administering an effective amount of the polypeptide according to claim 1 and a fibrinolytic agent to induce the desired level of fibrinolytic activity without causing hemorrhage. 6. A method of fibrinolytic therapy in a patient in need thereof, said method comprising administering to the patient a thrombolytic dosage of a thrombolytic agent and thereafter administering an effective supplemental dosage of the polypeptide according to claim 1 in an amount that reduces hemorrhage or side effects, said supplemental dosage of the polypeptide being administered once every 1 to 10 days for the duration of the therapy. 7. The method of fibrinolytic therapy according to claim 6, wherein the thrombolytic agent includes tPA or uPA and is administered at a standard clinical thrombolytic dosage. 8. The method of fibrinolytic therapy according to claim 6, wherein the supplemental dosage of the polypeptide is a bolus up to 500 mg. 9. A method of reducing hemorrhage in a patient receiving said method comprising administering to the patient once every 1 to 10 days a bolus of an amount of the polypeptide according to claim 1, wherein said polypeptide subsequently inhibits vasoactive effects of plasminogen activators including tPA or uPA given at standard clinical dosages.

Details for Patent 7,271,143

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2021-07-10
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2021-07-10
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786	10/30/1996		2021-07-10